Posted by Michael Wonder on 20 Aug 2018
U.S. FDA grants fast track designation to Aravive Biologics’ AVB-S6-500
20 August 2018 - Aravive Biologics announced today that the U.S. FDA has granted fast track designation to AVB-S6-500 as a potential treatment for platinum-resistant recurrent ovarian cancer.
AVB-S6-500 is a novel high-affinity, soluble Fc-fusion protein designed to block the activation of the GAS6-AXL signalling pathway by intercepting the binding of GAS6 to its receptor AXL. Research has shown GAS6-AXL signalling to be a key molecular pathway that promotes tumor growth and metastases, as well as immune evasion and resistance to other anticancer agents. AXL and GAS6 expression correlate with poor prognosis in cancer.
Results of a Phase 1 study of AVB-S6-500 in healthy volunteers showed a favourable safety profile, with no reported serious or dose-limiting adverse events.
